International Assets Investment Management LLC Buys 186,271 Shares of Kenvue Inc. (NYSE:KVUE)

International Assets Investment Management LLC increased its stake in Kenvue Inc. (NYSE:KVUE) by 1,748.0% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 196,927 shares of the company’s stock after acquiring an additional 186,271 shares during the period. International Assets Investment Management LLC’s holdings in Kenvue were worth $4,240,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Clearstead Advisors LLC purchased a new position in Kenvue in the third quarter worth $25,000. Planned Solutions Inc. purchased a new position in Kenvue in the fourth quarter worth $27,000. EverSource Wealth Advisors LLC purchased a new position in Kenvue in the third quarter worth $28,000. AdvisorNet Financial Inc purchased a new position in Kenvue in the third quarter worth $28,000. Finally, Global Retirement Partners LLC purchased a new position in Kenvue in the third quarter worth $28,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on KVUE shares. The Goldman Sachs Group initiated coverage on shares of Kenvue in a research report on Friday, March 1st. They issued a “neutral” rating and a $20.00 target price for the company. Royal Bank of Canada cut their price target on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a research report on Friday, February 9th. JPMorgan Chase & Co. cut their price target on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, February 9th. William Blair initiated coverage on shares of Kenvue in a research report on Wednesday, April 3rd. They set a “market perform” rating for the company. Finally, Sanford C. Bernstein initiated coverage on shares of Kenvue in a research report on Thursday, April 11th. They set an “underperform” rating and a $18.00 price target for the company. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $24.85.

Kenvue Stock Down 0.1 %

Kenvue stock opened at $19.11 on Wednesday. The company has a current ratio of 1.12, a quick ratio of 0.78 and a debt-to-equity ratio of 0.69. The firm has a 50-day moving average of $19.85 and a 200-day moving average of $20.17. Kenvue Inc. has a 1-year low of $17.82 and a 1-year high of $27.80.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.03. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The company had revenue of $3.67 billion during the quarter, compared to analyst estimates of $3.78 billion. The firm’s quarterly revenue was down 2.7% on a year-over-year basis. On average, equities analysts expect that Kenvue Inc. will post 1.17 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, February 28th. Investors of record on Wednesday, February 14th were paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 4.19%. The ex-dividend date of this dividend was Tuesday, February 13th.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.